Lupus Research Institute awards $4.5 million to advance new science in lupus
Main Category: LupusArticle Date: 12 Oct 2005 - 3:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Following an intensive scientific review of the largest number of grant applications ever received--nearly double that of previous years--the national nonprofit Lupus Research Institute (LRI) has awarded $4.5 million in new grants to 15 scientists investigating highly promising novel research approaches to lupus.
Recipients culled from the pool of 81 applications from around the country will receive 3-year, $300,000 grants to pursue the type of research that the LRI defines as core to its mission: innovative and creative work, representing "outside the box" thinking that has the potential to make significant impact on the field of lupus research and on the estimated 1.5 million Americans living with this devastating autoimmune disease.
While often high-risk (9 of the new grants qualify as such), many of the projects that the five-year-old LRI is funding have already demonstrated the potential for "high-reward"--surging ahead in breakthroughs in understanding the cause, prevention and treatment strategies for the disease.
"The quality, novelty, and scope of these grants exceeded all our expectations," said Mark Shlomchik, MD, PhD, the LRI Novel Research Task Force Co-Chairman and Professor of Laboratory Medicine and Immunobiology at Yale University School of Medicine. "We're very impressed at the range of research areas represented--from basic immunology to human studies in the renal, neurological and cardiovascular systems that lupus attacks."
By appealing to researchers in many specialties, Shlomchik added, the LRI spurs novel approaches and collaborations not previously applied to lupus. A remarkable number--nearly half--of the 2005 grant recipients are bringing their scientific talents to the study of lupus for the first time.
A Proven Formula for Success
"The LRI novel research strategy is working," said Nicholas Chiorazzi, MD, Director of the Institute for Medical Research of the North Shore-LIJ Health System, and Co-Chairman of the LRI Novel Research Task Force. "It's supporting the level of new investigations that the NIH typically does not back, and then moving these ideas ahead to secure large federal funding at the end of the LRI grant cycle."
To date, more than 70 percent of the LRI investigators who have completed their projects have gone on to secure large-scale federal funding.
With the award of the new grants, the LRI now funds the largest number of privately supported scientific investigators in lupus nationwide. The scientists awarded $300,000 grants are:
Pascale Alard, Ph.D.
University of Louisville Research Foundation, Inc., KY
Title: Enhancing Immunoregulation to Prevent and/or Cure SLE
Felipe Andrade, M.D., Ph.D.
Johns Hopkins University, Baltimore, MD
Title: Exploring the Molecular Mechanisms Involved in Lupus Remission
Timothy W. Behrens, M.D.
University of Minnesota Medical School, Minneapolis, MN
Title: Serum Protein Biomarkers for Disease Activity in Human SLE
Janis Burkhardt, Ph.D.
Children's Hospital of Philadelphia, PA and the University of Pennsylvania
Title: Analysis of a Lupus-Associated HS1 Isoform
Marcus R. Clark, M.D.
University of Chicago, IL
Title: Pathobiology of Resistant B Lymphocytes in Human Lupus Nephritis
Christine M. Grimaldi, Ph.D.
Columbia University, New York, NY
Title: Genetic Basis for Estrogen-Exacerbated SLE
Roland G. Henry, Ph.D.
University of California, San Francisco, CA
Title: Neuropsychiatric Symptoms and Brain MRI Markers in SLE Patients
Daniel H. Kaplan, M.D., Ph.D.
Yale University School of Medicine, New Haven, CT
Title: Involvement of Plasmacytoid DCs in the Development of SLE
Greg E. Lemke, Ph.D.
The Salk Institute for Biological Studies, La Jolla, CA
Title: TAM Receptors - Their Function in Dendritic Cell Regulation and Role in Autoimmune Disease. Theresa T. Lu, M.D., Ph.D.
Hospital for Special Surgery, New York, NY
Title: Type 1 Interferons and Lymphoid Tissue Blood Vessel Growth in SLE
Amy S. Major, Ph.D.
Vanderbilt University School of Medicine, Nashville, TN
Title: Autoimmune Mechanisms of Enhanced Atherosclerosis in SLE
Marko Z. Radic, Ph.D.
University of Tennessee, Health Science Center, Memphis, TN
Title: Characteristics of Autoimmune Nucleosome Complexes Generated in Apoptosis
Inez Rogatsky, Ph.D.
Hospital for Special Surgery, New York, NY
Title: Regulation of Interferon Production: IRF3 as a Transcriptional Target for the Glucocorticoid Receptor
Martin Weigert, Ph.D.
University of Chicago, IL
Title: Light Chain Editors and Autoimmunity
Zhixin (Jason) Zhang, Ph.D.
University of Alabama at Birmingham, AL
Title: Affinity Maturation of Anti-DNA Antibodies during the Germinal Center Reaction in SLE Patients
For more information, visit LupusResearchInstitute.org
Visit our lupus section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/31907.php>
APA
http://www.medicalnewstoday.com/releases/31907.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




